A new TaqMan real-time PCR assay to detect Parachlamydia acanthamoebae and to monitor its co-existence with SARS-COV-2 among COVID-19 patients

• DOI: 10.1007/s11356-022-23227-x
• Publication Date: 2022-10-05T03:25:47Z
• Authors: Olfa Baccari; Mohamed Barkallah; Jihen Elleuch; Nourelhouda Ben Ayed; Amel Chtourou; Héla Karray-Hakim; Adenene Hammami; Philippe Michaud; Imen Fendri; Slim Abdelkafi
• Keywords: 0301 basic medicine; 03 medical and health sciences; COVID-19 Testing; SARS-CoV-2; Humans; Reproducibility of Results; COVID-19; Real-Time Polymerase Chain Reaction; Research Article; 3. Good health

Human respiratory infections caused by a large variety of microbial pathogens are the most common diseases responsible for hospitalization, morbidity and mortality. Parachlamydia acanthamoebae, a Chlamydia-related bacterium, has been found to be potentially associated with these diseases. An early and accurate diagnosis of this pathogen could be useful to avoid the potential respiratory complications linked especially to COVID-19 patients and to set suitable outbreak control measures. A TaqMan-PCR assay was developed to detect and quantify Parachlamydia acanthamoebae in environmental and clinical samples from patients of all ages with COVID-19. The selected hydrolysis probe displayed no cross-reaction with the closely related Chlamydia or the other tested pathogens. This q-PCR achieved good reproducibility and repeatability with a detection limit of about 5 DNA copies per reaction. Using this q-PCR assay, Parachlamydia acanthamoebae was detected in 2/78 respiratory specimens and 9/47 water samples. Only one case (1.3%) of Parachlamydia acanthamoebae and SARS-COV-2 co-infection was noticed. To our knowledge, the combination of these two respiratory pathogens has not been described yet. This new TaqMan-PCR assay represents an efficient diagnostic tool to survey Parachlamydia acanthamoebae on a large-scale screening programs and also during outbreaks.